高级检索
当前位置: 首页 > 详情页

Neutrophil and monocyte ratios to high-density lipoprotein cholesterol as biomarkers in non-dipping hypertension

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Wuhan Univ, Tongren Hosp, Wuhan Hosp 3, Dept Gen Med, Wuhan, Peoples R China
出处:
ISSN:

关键词: Neutrophil monocyte high-density lipoprotein cholesterol (HDL-C) biomarkers non-dipping hypertension

摘要:
Objective To investigate the level and significance of neutrophils to high-density lipoprotein cholesterol ratio (NHR) and monocytes to high-density lipoprotein cholesterol ratio (MHR) in patients with non-dipping hypertension. Methods A total of 228 patients were retrospectively enrolled in the study. They were divided into the dipping hypertension group (n = 76), the non-dipping hypertension group (n = 77) and the control group (n = 75) according to 24-h ambulatory blood pressure monitoring system (ABPM) recordings. NHR and MHR were calculated and compared statistically. Receiver operating characteristic (ROC) curve analyses were performed for NHR and MHR. Binary logistic regression analyses were introduced to investigate the independent associations of NHR and MHR with non-dipping hypertension. Results The NHR and MHR were significantly higher in the non-dipping hypertension group compared with the control group (p = .001, p < .001, respectively) and the dipping hypertension group (p = .039, p = .003, respectively). According to ROC curve analyses, NHR>73.35 and MHR>7.54 were regarded as high-risk groups. The area under the curve (AUC) was 0.642 (p < .001) for NHR and 0.718 (p < .001) for MHR. In multivariate analysis, compared with NHR, only MHR was still recognized as a marker for detection of non-dipping hypertension (odds ratio [OR]: 1.208, 95% confidence interval [CI]: 1.076 to 1.356, p = .001). Conclusions Our data indicated that not NHR but MHR as new composite marker of inflammation and lipid metabolism may predict non-dipping hypertension to some extent.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 4 区 医学
小类 | 4 区 药学 4 区 外周血管病
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 外周血管病 4 区 药学
JCR分区:
出版当年[2021]版:
Q4 PERIPHERAL VASCULAR DISEASE Q4 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q3 PERIPHERAL VASCULAR DISEASE Q3 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Wuhan Univ, Tongren Hosp, Wuhan Hosp 3, Dept Gen Med, Wuhan, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Wuhan Univ, Tongren Hosp, Wuhan Hosp 3, Dept Gen Med, Wuhan, Peoples R China [*1]Wuhan Univ, Tongren Hosp, Wuhan Hosp 3, Dept Gen Med, 241 Pengliuyang Rd, Wuhan 430060, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:25463 今日访问量:0 总访问量:1498 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)